CIK 0000842023 · Large accelerated filer
BIO-TECHNE Corp
Sign in to watch- Ticker
- TECH
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Jun 30
- Incorporated
- MN
- Entity type
- operating
- EIN
- 411427402
- Phone
- 612-379-8854
- Business address
- 614 MCKINLEY PLACE NE, MINNEAPOLIS, MN
- Former names
- TECHNE CORP /MN/
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-06-09 | Kelderman Kim Pres. Diagnostics & Genom | Sale | −811 | $433.00 | $351K | 0 |
| 2021-06-07 | Hippel James Chief Financial Officer | Option exercise | +9,942 | $106.59 | $1.1M | 19,079 |
| 2021-06-07 | Hippel James Chief Financial Officer | Sale | −1,507 | $419.88 | $633K | 17,572 |
| 2021-06-07 | Hippel James Chief Financial Officer | Sale | −2,029 | $420.66 | $854K | 15,543 |
| 2021-06-07 | Hippel James Chief Financial Officer | Sale | −2,396 | $421.93 | $1.0M | 13,147 |
| 2021-06-07 | Hippel James Chief Financial Officer | Sale | −2,000 | $422.81 | $846K | 11,147 |
| 2021-06-07 | Hippel James Chief Financial Officer | Sale | −1,700 | $423.74 | $720K | 9,447 |
| 2021-06-07 | Hippel James Chief Financial Officer | Sale | −310 | $424.59 | $132K | 9,137 |
| 2021-06-07 | Hippel James Chief Financial Officer | Option exercise · Stock Options (Right to Buy) | −9,942 | 30,000 | ||
| 2021-05-25 | Kelderman Kim Pres. Diagnostics & Genom | Sale | −845 | $424.00 | $358K | 811 |
| 2021-05-25 | Kummeth Charles R. Chief Executive Officer | Option exercise | +36,849 | $94.35 | $3.5M | 195,690 |
| 2021-05-25 | Kummeth Charles R. Chief Executive Officer | Shares withheld for taxes | −21,305 | $420.12 | $9.0M | 174,385 |
| 2021-05-25 | Kummeth Charles R. Chief Executive Officer | Option exercise · Stock Options (Right to Buy) | −36,849 | 0 | ||
| 2021-05-01 | Kelderman Kim Pres. Diagnostics & Genom | Option exercise | +1,667 | 2,512 | ||
| 2021-05-01 | Kelderman Kim Pres. Diagnostics & Genom | Shares withheld for taxes | −856 | $427.49 | $366K | 1,656 |
| 2021-05-01 | Kelderman Kim Pres. Diagnostics & Genom | Option exercise · Restricted Stock Units | −1,667 | 0 | ||
| 2021-03-01 | Furlow Brenda S. SVP - General Counsel | Grant or award · Stock Options (Right to Buy) | +10,997 | 10,997 | ||
| 2021-02-16 | Kummeth Charles R. Chief Executive Officer | Option exercise | +30,000 | $94.35 | $2.8M | 176,269 |
| 2021-02-16 | Kummeth Charles R. Chief Executive Officer | Shares withheld for taxes | −17,428 | $411.00 | $7.2M | 158,841 |
| 2021-02-16 | Kummeth Charles R. Chief Executive Officer | Option exercise · Stock Options (Right to Buy) | −30,000 | 36,849 |
Page 34 of 53 · 1,043 trades